Penis (PeSCC)
- Home
- Cancer Infomation
Penile Squamous Cell Carcinoma (PeSCC)
Penile cancer is a rare malignancy, primarily presenting as Squamous Cell Carcinoma (SCC) in over 95% of cases. the clinical focus has shifted toward organ-sparing surgery and the utilization of dynamic sentinel node biopsies to reduce the significant morbidity historically associated with inguinal lymphadenectomy.
Etiology & Risk Factors
The oncogenesis of penile cancer typically follows two distinct pathways: HPV-mediated and non-HPV-mediated (chronic inflammation).
Environmental & Lifestyle Triggers:
- Human Papillomavirus (HPV): Associated with ~40–50% of cases, particularly types 16, 18, and 33.
- Phimosis & Poor Hygiene: Chronic accumulation of smegma under the prepuce leads to persistent inflammation. Circumcision in infancy is highly protective.
- Tobacco Use: Smoking increases the risk 3- to 4-fold, likely due to the concentration of tobacco metabolites in the preputial space.
- Chronic Inflammation: Conditions such as Balanitis Xerotica Obliterans (BXO) or Lichen Sclerosus are significant precursors.
2. Genetic Predispositions
- TP53 & CDKN2A (p16): Common mutations in both HPV-positive and negative pathways.
- PIK3CA Pathway: Mutations here are increasingly targeted in clinical trials for advanced disease.
- Epigenetic Alterations: Hypermethylation of tumor suppressor genes is a hallmark of aggressive PeSCC.
Clinical Manifestations (Symptoms)
Detection is often delayed by patient-related factors such as guilt, shame, or the masking of symptoms by phimosis.
Early-Stage Symptoms:
- Painless Lesion: Often presents as a small induration, ulcer, or exophytic growth on the glans or prepuce.
- Discharge: Foul-smelling discharge or bleeding under the foreskin.
- Phimosis: New-onset inability to retract the foreskin.
Advanced-Stage Symptoms:
- Palpable Inguinal Nodes: Firm, non-tender masses in the groin (present in ~50% of patients at diagnosis, though 25% are inflammatory).
- Erosion: Destruction of the glans or corpora cavernosa.
- Systemic Symptoms: Fatigue, weight loss, and anemia.
Paraneoplastic Syndromes:
- Hypercalcemia: Occasionally seen in advanced PeSCC due to the production of parathyroid hormone-related protein (PTHrP) by squamous cells.
Diagnostic Workup
Accuracy in the initial biopsy is critical to determine the depth of invasion and the necessity of nodal surgery.
- Biopsy: Punch or Incisional Biopsy is preferred over excisional biopsy for larger lesions to plan margins. It must include the underlying stroma to assess the depth of invasion.
- HPV Testing: Routine p16 immunohistochemistry (IHC) or HPV-DNA PCR is standard to assist in prognostication and clinical trial eligibility.
Common Investigations & Staging
Key imaging modalities and their clinical rationale for staging penile cancer.
Imaging Modalities & Rationale
- Penile MRI (with Pharmacological Erection): Using prostaglandin injection to induce tumescence allows for superior visualization of corpora cavernosa invasion, which is the deciding factor between organ-sparing and partial penectomy.
- Ultrasound (High Frequency): Effective for measuring the thickness of the primary lesion and assessing superficial inguinal nodes.
- CT Abdomen/Pelvis: Routine for assessing pelvic lymphadenopathy and visceral metastasis in patients with biopsy-proven inguinal node involvement.
- 18F-FDG PET-CT: In 2026, PET-CT is the gold standard for nodal staging in patients with palpable groin nodes to identify occult pelvic nodes or distant spread.
Treatment Overview
Comprehensive surgical, radiation, and systemic treatment strategies for penile cancer.
1. Surgery
- Organ-Sparing (Glansectomy/Wide Local Excision): Preferred for Early lesions when technically feasible, often utilizing split-thickness skin grafts for reconstruction.
- Partial/Radical Penectomy: Reserved for deep invasive & advanced lesions where a 5mm-1cm margin cannot be achieved without sacrificing the organ.
- Dynamic Sentinel Node Biopsy (DSNB): For patients with clinically negative groins (cN0) but high-risk primary tumors (≥T1G2), DSNB using radiotracer and patent blue dye is the standard to avoid the morbidity of radical dissection.
- Robotic-Assisted Inguinal Lymphadenectomy (RAIL): Minimal invasive nodal dissection is the standard of care, significantly reducing skin necrosis and lymphedema compared to open surgery.
3. Systemic Therapy
- Neoadjuvant Chemotherapy: The TIP Regimen (Paclitaxel, Ifosfamide, Cisplatin) is utilized for bulky or fixed inguinal nodes to downstage disease before surgery.
- Immunotherapy: Pembrolizumab or Nivolumab is increasingly used for advanced/metastatic disease, especially in HPV-positive tumors or those with high Tumor Mutational Burden (TMB).
2. Radiotherapy
- Brachytherapy: An excellent organ-sparing option for small (T1-T2) lesions of the glans in selected patients, offering high local control rates.
- External Beam (IMRT): Used as adjuvant therapy for N2/N3 disease or as palliative treatment for unresectable groin masses.
Emerging Therapies
- Antibody-Drug Conjugates (ADCs): New ADCs targeting HER2 (in overexpressing SCC) and EGFR are entering second-line clinical protocols.
- AI-Driven Margin Assessment: Intraoperative AI-enhanced fluorescence imaging is being used to ensure R0 resections while maximizing the preservation of healthy penile tissue.
- Therapeutic HPV Vaccines: DNA-based vaccines targeting E6/E7 oncoproteins are being used as adjuncts to immunotherapy for recurrent HPV-positive PeSCC.
Medical Disclaimer
This guide is intended for healthcare professionals and clinical researchers.
It reflects oncology standards as of 2026.
Treatment should always be discussed within a multidisciplinary tumor board (MDT), including urologists, oncologists, and radiologists.